- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5594
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma ; day:7 ; month:3 ; year:2018 ; pages:1-13
Oncogene ; (7.3.2018), 1-13
- Urheber
-
Bolin, Sara
- Beteiligte Personen und Organisationen
-
Borgenvik, Anna
Persson, Camilla U.
Sundström, Anders
Qi, Jun
Bradner, James E.
Weiss, William A.
Cho, Yoon-Jae
Weishaupt, Holger
Swartling, Fredrik J.
SpringerLink (Online service)
- DOI
-
10.1038/s41388-018-0135-1
- URN
-
urn:nbn:de:1111-201805107998
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bolin, Sara
- Borgenvik, Anna
- Persson, Camilla U.
- Sundström, Anders
- Qi, Jun
- Bradner, James E.
- Weiss, William A.
- Cho, Yoon-Jae
- Weishaupt, Holger
- Swartling, Fredrik J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Targeting MYC in high risk medulloblastoma
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Targeting MYC in high risk medulloblastoma
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Mechanisms of resistance to inhibitors of bromodomain and extra-terminal domain (BET) proteins in MYC-driven medulloblastoma
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Targeting MYC in high risk medulloblastoma
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Dietary compound resveratrol is a pan-BET bromodomain inhibitor